PHARMAERO ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  22.5% 12.1% 14.6% 19.4% 18.1%  
Credit score (0-100)  5 20 13 6 7  
Credit rating  B BB BB B B  
Credit limit (kDKK)  0.0 0.0 0.0 -0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  29 149 0 0 0  
Gross profit  29.0 149 -1,266 -638 -18.6  
EBITDA  -14,001 -2,095 -1,266 -638 -18.6  
EBIT  -14,001 -2,095 -1,266 -638 -18.6  
Pre-tax profit (PTP)  -14,059.0 -2,129.0 -1,297.0 -650.6 -20.1  
Net earnings  -12,231.0 -1,773.0 -1,297.0 -650.6 -20.1  
Pre-tax profit without non-rec. items  -14,059 -2,129 -1,297 -651 -20.1  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  6,586 4,813 3,516 72.0 51.9  
Interest-bearing liabilities  0.0 0.0 0.0 11.5 19.0  
Balance sheet total (assets)  7,209 5,260 3,534 93.5 80.9  

Net Debt  -4,422 -4,631 -3,517 -79.3 -61.9  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  29 149 0 0 0  
Net sales growth  0.0% 413.8% -100.0% 0.0% 0.0%  
Gross profit  29.0 149 -1,266 -638 -18.6  
Gross profit growth  0.0% 413.8% 0.0% 49.6% 97.1%  
Employees  1 0 0 0 0  
Employee growth %  0.0% -100.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  7,209 5,260 3,534 94 81  
Balance sheet change%  -65.4% -27.0% -32.8% -97.4% -13.5%  
Added value  -14,001.0 -2,095.0 -1,266.0 -638.2 -18.6  
Added value %  -48,279.3% -1,406.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 1.0 -1.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  -48,279.3% -1,406.0% 0.0% 0.0% 0.0%  
EBIT %  -48,279.3% -1,406.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -48,279.3% -1,406.0% 100.0% 100.0% 100.0%  
Net Earnings %  -42,175.9% -1,189.9% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  -42,175.9% -1,189.9% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  -48,479.3% -1,428.9% 0.0% 0.0% 0.0%  
ROA %  -99.8% -33.6% -28.8% -35.2% -21.3%  
ROI %  -210.0% -36.8% -30.4% -35.5% -24.1%  
ROE %  -183.5% -31.1% -31.1% -36.3% -32.4%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  91.4% 91.5% 99.5% 77.0% 64.2%  
Relative indebtedness %  2,148.3% 300.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  -13,100.0% -2,808.1% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  31.6% 221.1% 277.8% 12.4% 332.6%  
Gearing %  0.0% 0.0% 0.0% 16.0% 36.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 216.9% 9.6%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  11.6 11.8 196.3 4.3 2.8  
Current Ratio  11.6 11.8 196.3 4.3 2.8  
Cash and cash equivalent  4,422.0 4,631.0 3,517.0 90.8 80.9  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 365.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  24,858.6% 3,530.2% 0.0% 0.0% 0.0%  
Net working capital  6,586.0 4,813.0 3,516.0 72.0 51.9  
Net working capital %  22,710.3% 3,230.2% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  29 0 0 0 0  
Added value / employee  -14,001 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -14,001 0 0 0 0  
EBIT / employee  -14,001 0 0 0 0  
Net earnings / employee  -12,231 0 0 0 0